Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 1.

Table. 1.

Patient characteristics

Variables EPG (n=42) LPG (n=59) p-value
Sex (male:female) 24:18 41:18 0.202
Age 62.29±10.59 66.00±9.99 0.075
Pre-OP laboratory findings
Albumin (g/dl) 3.53±0.44 3.55±0.45 0.845
AST (IU/L) 42.36±28.37 39.97±23.20 0.643
ALT (IU/L) 35.79±25.81 45.44±40.64 0.178
GGT (IU/L) 445.98±453.69 344.15±291.17 0.205
CEA (ng/ml) 4.13±5.87 3.82±5.66 0.969
CA 19-9 (U/ml) 1166.77±3339.59 468.03±1071.22 0.197
Total bilirubin (mg/dl) 1.69±1.08 1.36±0.79 0.099
Highest total bilirubin (mg/dl) 8.33±6.30 6.87±6.53 0.266
Neoadjuvant CCRT 6 (14.3%) 26 (44.1%) 0.002
PVE 3 (7.1%) 14 (23.7%) 0.028
Bismuth-Corlette type
I 3 (7.1%) 2 (3.4%)
II 8 (19.0%) 8 (13.6%)
IIIa 8 (19.0%) 26 (44.1%)
IIIb 4 (9.5%) 9 (15.3%)
IV 19 (45.2%) 14 (23.7%)
AJCC stage
0 1 (2.4%) 2 (3.4%)
I 1 (2.4%) 2 (3.4%)
II 20 (47.6%) 28 (47.5%)
IIIA 0 (0%) 7 (11.9%)
IIIB 18 (42.9%) 17 (28.8%)
IVB 2 (4.8%) 3 (5.1%)

EPG, early period group; LPG, late period group; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; CCRT, concurrent chemo-radiation therapy; PVE, portal vein embolization; AJCC, American Joint Committee on Cancer; LN, lymph node

Ann Hepatobiliary Pancreat Surg 2021;25:54-61 https://doi.org/10.14701/ahbps.2021.25.1.54
© 2021 Ann Hepatobiliary Pancreat Surg